| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Robert E. George is Director at MBRX. Robert E. George's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $122K at current prices.
Net of sales, the MBRX filings show accumulation of 15,493 shares.
Robert E. George has 13 Form 4 filings on record from September 2016 to November 2025, all as Director at Moleculin Biotech (MBRX), 2016–2025.
The 14 reported transactions were 12 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $11K and no sales.
The largest open-market purchase was 14,493 shares of MBRX at an average $0.69 on December 26, 2023, about $10K. Twelve months later MBRX was down 82%.